Author

Alastair M. Thompson

Observed name: Alastair Thompson

Institutions: Baylor College of Medicine, Dan L Duncan Comprehensive Cancer Center

Observed institutions: Baylor College of Medicine, Dan L Duncan Comprehensive Cancer Center

OpenAlex ID: A5135456351

Ecotypes of triple-negative breast cancer in response to chemotherapy

2026 · Yun Yan, Yiyun Lin, et al. · Nature · 5

Effects of ovarian ablation or suppression on breast cancer recurrence and survival: patient-level meta-analysis of 15 000 women in 23 randomised trials

2026 · Rosie Bradley, Jeremy Braybrooke, et al. · The Lancet · 5

The ARTEMIS trial identifies immune activation as a key predictor of neoadjuvant chemotherapy response in triple-negative breast cancer

2026 · Sahil Seth, Clinton Yam, et al. · Breast Cancer Research · 1

Non-BRCA germline pathogenic variants and response to neoadjuvant systemic therapy in triple-negative breast cancer patients enrolled in a prospective clinical trial

2026 · Kamaria L. Lee, Clinton Yam, et al. · Breast Cancer Research and Treatment

High-depth whole genome sequencing of premalignant breast lesions reveals rearrangement hotspots and personalized management opportunities

2026 · Lucia Chmelova, Helen R. Davies, et al. · Nature Communications

Enabling DCIS subtyping: leveraging foundation models for robust grading and molecular biomarker scoring

2026 · S. Doyle, M. A. Oerlemans, et al. · npj Breast Cancer

Patient-derived xenograft models of primary breast cancer for preclinical evaluation of neoadjuvant therapies

2026 · Stefan J. Hutten, Stefan J. Hutten, et al. · Science Translational Medicine

Works count: 8

Citation count: 10

H-index: 2

I10-index: